These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8634515)

  • 41. the role of autoantibody and immune complexes in the pathogenesis of Guillain-Barré syndrome.
    Cook SD; Dowling PC
    Ann Neurol; 1981; 9 Suppl():70-9. PubMed ID: 6452856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipooligosaccharide of Campylobacter jejuni prevents myelin-specific enteral tolerance to autoimmune neuritis--a potential mechanism in Guillain-Barre syndrome?
    Jung S; Zimmer S; Lüneberg E; Frosch M; Karch H; Korn T; Toyka KV
    Neurosci Lett; 2005 Jun 10-17; 381(1-2):175-8. PubMed ID: 15882812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are Th17 cells and their cytokines a therapeutic target in Guillain-Barré syndrome?
    Wu X; Wang J; Liu K; Zhu J; Zhang HL
    Expert Opin Ther Targets; 2016; 20(2):209-22. PubMed ID: 26357850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?].
    Martínez Yélamos A; Huerta Villanueva M; Olivé Plana M; Montero Homs J; Serra Catafau J; Martínez-Matos JA
    Neurologia; 1998 Apr; 13(4):166-9. PubMed ID: 9608755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical relevance of the determination of anti-GQ1b antibodies in Miller Fisher and Guillain-Barré syndromes.
    Goffette S; Jeanjean A; Pierret F; Peeters A; Sindic CJ
    Acta Neurol Belg; 1998 Dec; 98(4):322-6. PubMed ID: 9922819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A case of post-rubella Guillain-Barré syndrome associated with ulcerative colitis].
    Saito M; Hozumi I; Kawakami A; Tsuji S
    Rinsho Shinkeigaku; 1994 Nov; 34(11):1121-4. PubMed ID: 7729092
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Guillain-Barré syndrome.
    Pemberton L
    Nurs Times; 1998 Nov 18-24; 94(46):50-3. PubMed ID: 9923382
    [No Abstract]   [Full Text] [Related]  

  • 48. Experimental allergic neuritis and Guillain-Barré syndrome: immune mechanisms. A short review.
    Hartung HP
    Acta Neurol Belg; 1994; 94(2):120-3. PubMed ID: 8036878
    [No Abstract]   [Full Text] [Related]  

  • 49. [Demyelination and autoimmunity].
    Lebar R
    Pathol Biol (Paris); 1987 Mar; 35(3):275-83. PubMed ID: 3295694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Guillain-Barré syndrome; pathogenesis and treatment.
    Van Der Meché FG
    Rev Neurol (Paris); 1996 May; 152(5):355-8. PubMed ID: 8881429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Guillain-Barré syndrome associated with cytomegalovirus infection after kidney transplantation].
    Lloveras JJ; Larrue V; Delisle MB; Tack I; Icart J; Dupré C; Ton That H; Durand D; Suc JM
    Presse Med; 1994 Jun; 23(21):976-8. PubMed ID: 7937644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome.
    Koski CL; Gratz E; Sutherland J; Mayer RF
    Ann Neurol; 1986 Jun; 19(6):573-7. PubMed ID: 3729311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Guillain-Barré syndrome treated with high doses of immunoglobulins by the intravenous route: 4 cases].
    Uldry PA; Bogousslavsky J; Regli F
    Rev Neurol (Paris); 1991; 147(8-9):573-6. PubMed ID: 1962066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Eighty three years of the Guillain-Barré syndrome: clinical and immunopathologic aspects, current and future treatments.
    Toyka KV
    Rev Neurol (Paris); 1999 Oct; 155(10):849-56. PubMed ID: 10546299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Morphologic study on experimental allergic neuritis mediated by T cell line specific for bovine P2 protein in Lewis rats.
    Izumo S; Linington C; Wekerle H; Meyermann R
    Lab Invest; 1985 Aug; 53(2):209-18. PubMed ID: 2410663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can IFN-γ be a therapeutic target in Guillain-Barré syndrome?
    Zhang HL; Wu L; Wu X; Zhu J
    Expert Opin Ther Targets; 2014 Apr; 18(4):355-63. PubMed ID: 24479493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C associated with Guillain-Barré syndrome.
    Lacaille F; Zylberberg H; Hagège H; Roualdès B; Meyrignac C; Chousterman M; Girot R
    Liver; 1998 Feb; 18(1):49-51. PubMed ID: 9548267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Guillain-Barré syndrome with autoimmune hemolytic anemia following acute viral hepatitis.
    Perseghin P; Balduini CL; Piccolo G; Bertolino G; Bellusci M; Scelsi R; Mauri C
    Ital J Neurol Sci; 1985 Dec; 6(4):447-50. PubMed ID: 4086264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased proliferation of blood mononuclear cells after plasmapheresis treatment of patients with demyelinating disease.
    Dau PC
    J Neuroimmunol; 1990 Nov; 30(1):15-21. PubMed ID: 2229403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guillain-Barré syndrome after heart transplantation.
    Baldwin RT; Pierce RR; Frazier OH
    J Heart Lung Transplant; 1992; 11(4 Pt 1):817-9. PubMed ID: 1323331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.